CollPlant Biotechnologies (NASDAQ:CLGN) Trading 10.2% Higher – Time to Buy?

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) traded up 10.2% on Thursday . The stock traded as high as $0.3854 and last traded at $0.3523. 195,749 shares traded hands during mid-day trading, an increase of 96% from the average session volume of 99,994 shares. The stock had previously closed at $0.3198.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CLGN. Weiss Ratings reissued a “sell (e+)” rating on shares of CollPlant Biotechnologies in a report on Wednesday, January 21st. D. Boral Capital lowered CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.50.

CollPlant Biotechnologies Trading Up 1.3%

The firm has a market cap of $5.14 million, a P/E ratio of -0.26 and a beta of 2.75. The business has a 50-day moving average of $0.56 and a two-hundred day moving average of $1.44.

Institutional Investors Weigh In On CollPlant Biotechnologies

Institutional investors have recently made changes to their positions in the stock. AMH Equity Ltd grew its position in shares of CollPlant Biotechnologies by 24.3% in the 3rd quarter. AMH Equity Ltd now owns 200,000 shares of the company’s stock valued at $538,000 after buying an additional 39,151 shares during the last quarter. Pinnacle Associates Ltd. grew its position in shares of CollPlant Biotechnologies by 9.9% in the 4th quarter. Pinnacle Associates Ltd. now owns 557,193 shares of the company’s stock valued at $780,000 after buying an additional 50,000 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC grew its position in shares of CollPlant Biotechnologies by 7.7% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 588,717 shares of the company’s stock valued at $1,584,000 after buying an additional 41,850 shares during the last quarter. Institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.